U.S. markets close in 3 hours 6 minutes
  • S&P 500

    3,773.33
    +94.90 (+2.58%)
     
  • Dow 30

    30,194.24
    +703.35 (+2.38%)
     
  • Nasdaq

    11,123.96
    +308.53 (+2.85%)
     
  • Russell 2000

    1,770.68
    +61.81 (+3.62%)
     
  • Crude Oil

    86.35
    +2.72 (+3.25%)
     
  • Gold

    1,736.30
    +34.30 (+2.02%)
     
  • Silver

    21.25
    +0.66 (+3.21%)
     
  • EUR/USD

    0.9969
    +0.0142 (+1.45%)
     
  • 10-Yr Bond

    3.6150
    -0.0360 (-0.99%)
     
  • GBP/USD

    1.1449
    +0.0129 (+1.14%)
     
  • USD/JPY

    144.1890
    -0.4310 (-0.30%)
     
  • BTC-USD

    20,012.22
    +622.09 (+3.21%)
     
  • CMC Crypto 200

    454.81
    +9.37 (+2.10%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

·1 min read
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD-G